Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma
I'm PortAI, I can summarize articles.
Konruns announced that it has received approval from the National Medical Products Administration to conduct clinical trials for KC1036 in combination with PD-1 antibodies and platinum-based chemotherapy as first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma. KC1036 is a Class 1 innovative drug independently developed by the company, which has anti-tumor activity and good safety. Clinical research has been conducted in multiple indications, with over 300 participants involved
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments